Abstract: See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/357709366 Effect of convalescent plasma as complementary treatment in patients with moderate COVID ‐19 infection Article in Transfusion Medicine · January 2022 DOI: 10.1111/tme.12851 CITATIONS READS 5 31 17 authors, including: Manuel Baldeon Augusto Maldonado Universidad Internacional del Ecuador Universidad San Francisco de Quito (USFQ) 89 PUBLICATIONS 1,121 CITATIONS 19 PUBLICATIONS 64 CITATIONS SEE PROFILE SEE PROFILE Miguel Jacob Ochoa Andrade Francisco Xavier Mora Toro Central University of Ecuador Instituto Ecuatoriano de Seguridad Social 12 PUBLICATIONS 5 CITATIONS 11 PUBLICATIONS 66 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: LMC-Helicobacter View project Chronic non-communicable diseases View project All content following this page was uploaded by Augusto Maldonado on 22 June 2022. The user has requested enhancement of the SEE PROFILE Received: 8 September 2021 Revised: 13 December 2021 Accepted: 30 December 2021 DOI: 10.1111/tme.12851 ORIGINAL ARTICLE Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection
n1 Manuel E. Baldeo | Augusto Maldonado2,3 | Miguel Ochoa-Andrade4 |
nica Pesantez5 | Marco Herdoiza5 | Gerardo Granja4 | Carolina Largo3 | Mo
pez3 | Marco Bonifaz4 | Hugo Espejo4 | Francisco Mora4 | Patricio Abril-Lo
nica Pacheco6 | Rafael Salazar6 | Lady Karen Robles Armijo6 | Vero Steffy Reinthaller6 | Federico Zertuche7 1 Escuela de Medicina, Facultad de Ciencias Médicas, de la Salud y de la Vida, Universidad Internacional del Ecuador, Quito, Ecuador | Marco Fornasini1 Abstract Introduction: South America is one of the regions most affected by the COVID-19 2 Escuela de Medicina, Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Quito, Ecuador
n Ministerio de Salud Pública, Coordinacio Zonal 9, Hospital General Docente de
n, Quito, Ecuador Caldero 3 4 Instituto Ecuatoriano de Seguridad Social, Hospital General Quito Sur - IESS, Quito, Ecuador 5 Hemocentro, Cruz Roja Ecuatoriana, Quito, Ecuador
n Ministerio de Salud Pública, Coordinacio Zonal 9, Hospital Pablo Arturo Suarez, Quito, Ecuador 6 pandemic. Specific and affordable treatments are needed to treat SARS-CoV-2 infection. Evidence regarding the use of convalescent plasma in COVID-19 patients is still limited. We compared the safety and efficacy of COVID-19-convalescent plasma administration as a complement to standard treatment in the early management of patients with moderate SARS-CoV-2 infection. Methods: We carried out a random double blinded, placebo-controlled trial that compared standard treatment plus convalescent plasma (CP) or plus non-convalescent plasma in the management of COVID-19 patients. The main outcome was survival and secondary endpoints included: length of hospitalisation (LOH), days from treatment to discharge, time to clinical improvement or death within a 28-day period, and Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito, Ecuador adverse reactions to treatment. Correspondence
n, Escuela de Medicina, Manuel E. Baldeo survival, RR = 1.003, 95% CI (0.3938, 2.555). These results led to terminate the RCT pre- 7 Facultad de Ciencias Médicas, de la Salud y de la Vida, Universidad Internacional del Ecuador,
n..